HPV type 16 protein E7 HLA-A2 binding peptides are immunogenic but not processed and presented

Immunology Letters

Volumn 71, Issue 1, 2000, Pages 55-59

  Bauer, Marc ^a   Wagner, Hermann ^a   Lipford, Grayson B ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antigen processing; HLA A2; Human papillomavirus

Indexed keywords

BINDING PROTEIN; HLA A2 ANTIGEN; PEPTIDE; PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; VACCINATION; WART VIRUS;

ANIMALS; ANTIGEN PRESENTATION; CELL LINE; HLA-A2 ANTIGEN; HUMANS; MICE; MICE, TRANSGENIC; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033956210     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-2478(99)00170-4     Document Type: Article

References (24)

1. Parkin D.M., Stjernsward J., Muir C.S. Bull.World Health Organ. 62:1984;163-182.
2. Zur Hausen H. Virology. 184:1991;9-13.
3. Schiffman M.H., Bauer H.M., Hoover R.N., Glass A.G., Cadell D.M., Rush B.B. et al. J. Natl. Cancer Inst. 85:1993;958-964.
4. De Villiers E.M. J. Virol. 63:1989;4898-4903.
5. Lorincz A.T., Reid R., Jenson A.B., Greenberg M.D., Lancaster W., Kurman R.J. Obstet. Gynecol. 79:1992;328-337.
6. Von Knebel D., Bauknecht T., Bartsch D., Zur Hausen H. Proc. Natl. Acad. Sci. USA. 88:1991;1411-1415.
7. Von Knebel D., Oltersdorf T., Schwarz E., Gissmann L. Cancer Res. 48:1988;3780-3786.
8. Halpert R., Fruchter R.G., Sedlis A., Butt K., Boyce J.G., Sillman F.H. Obstet. Gynecol. 68:1986;251-258.
9. Schwartz R.H. Annu. Rev. Immunol. 3:1985;237-261.
10. Townsend A.R., Gotch F.M., Davey J. Cell. 42:1985;457-467.
11. Falk K., Rotzschke O., Stevanovic S., Jung G., Rammensee H.G. Nature. 351:1991;290-296.
12. Chen L., Mizuno M.T., Singhal M.C., Hu S.L., Galloway D.A., Hellstrom I. et al. J. Immunol. 148:1992;2617-2621.
13. Chen L.P., Thomas E.K., Hu S.L., Hellstrom I., Hellstrom K.E. Proc. Natl. Acad. Sci. USA. 88:1991;110-114.
14. Feltkamp M.C., Smits H.L., Vierboom M.P., Minnaar R.P., de Jongh B.M., Drijfhout J.W. et al. Eur. J. Immunol. 23:1993;2242-2249.
15. Vitiello A., Marchesini D., Furze J., Sherman L.A., Chesnut R.W. J. Exp. Med. 173:1991;1007-1015.
16. Carbone F.R., Moore M.W., Sheil J.M., Bevan M.J. J. Exp. Med. 167:1988;1767-1779.
17. Evans C., Bauer S., Grubert T., Brucker C., Baur S., Heeg K. et al. Cancer Immunol. Immunother. 42:1996;151-160.
18. Baas E.J., van Santen H.M., Kleijmeer M.J., Geuze H.J., Peters P.J., Ploegh H.L. J. Exp. Med. 176:1992;147-156.
19. Kast W.M., Brandt R.M., Drijfhout J.W., Melief C.J. J. Immunother. 14:1993;115-120.
20. Lipford G.B., Wagner H., Heeg K. Vaccine. 12:1994;73-80.
21. Ressing M.E., Sette A., Brandt R.M., Ruppert J., Wentworth P.A., Hartman M. et al. J. Immunol. 154:1995;5934-5943.
22. Lipford G.B., Bauer S., Wagner H., Heeg K. Vaccine. 13:1995;313-320.
23. Wentworth P.A., Sette A., Celis E., Sidney J., Southwood S., Crimi C. et al. Int. Immunol. 8:1996;651-659.
24. Ressing M.E., van Driel W.J., Celis E., Sette A., Brandt M.P., Hartman M., Anholts J.D. et al. Cancer Res. 56:1996;582-588.